Palivizumab

Last Updated: 04/28/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 1486 publications

Nirsevimab in High-Risk Infants in a Respiratory Syncytial Virus Prevention Strategy.

Nirsevimab in High-Risk Infants in a Respiratory Syncytial Virus Prevention Strategy.

Journal: JAMA network open
Published: April 10, 2026

Meta-analysis of the efficacy of palivizumab versus nirsevimab at preventing medically attended respiratory syncytial virus infections in non-hospitalized preterm infants.

Meta-analysis of the efficacy of palivizumab versus nirsevimab at preventing medically attended respiratory syncytial virus infections in non-hospitalized preterm infants.

Journal: Human vaccines & immunotherapeutics
Published: April 01, 2026

Prevention of respiratory syncytial virus in children

Prevention of respiratory syncytial virus in children

Journal: Ugeskrift for laeger
Published: February 25, 2026

Respiratory Syncytial Virus Infection Triggering a Pulmonary Hypertensive Crisis in a Boy With Prader-Willi Syndrome-Associated Sleep-Disordered Breathing.

Respiratory Syncytial Virus Infection Triggering a Pulmonary Hypertensive Crisis in a Boy With Prader-Willi Syndrome-Associated Sleep-Disordered Breathing.

Journal: Cureus
Published: February 19, 2026

Systematic Review: Efficacy, Safety Profile, and Cost-Effectiveness of Nirsevimab Versus Palivizumab for RSV Prevention in Children Under 24 Months.

Systematic Review: Efficacy, Safety Profile, and Cost-Effectiveness of Nirsevimab Versus Palivizumab for RSV Prevention in Children Under 24 Months.

Journal: Children (Basel, Switzerland)
Published: February 04, 2026

Identifying High-Cost RSV Hospitalizations at a Secondary Hospital in Japan.

Identifying High-Cost RSV Hospitalizations at a Secondary Hospital in Japan.

Journal: The Keio journal of medicine
Published: January 25, 2026

Respiratory syncytial virus epidemiology and effectiveness of infant nirsevimab: 2024 results from the Australian Sentinel Hospital Network (FluCAN-PAEDS).

Respiratory syncytial virus epidemiology and effectiveness of infant nirsevimab: 2024 results from the Australian Sentinel Hospital Network (FluCAN-PAEDS).

Journal: Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin
Published: January 16, 2026

Reliability of RSV Antigen Diagnostic Tests in the Presence of Nirsevimab.

Reliability of RSV Antigen Diagnostic Tests in the Presence of Nirsevimab.

Journal: The Pediatric infectious disease journal
Published: January 06, 2026

Estimation of Public Health Impact with Use of Nirsevimab During the 2024-2025 RSV Season in the USA: a Modeling Study.

Estimation of Public Health Impact with Use of Nirsevimab During the 2024-2025 RSV Season in the USA: a Modeling Study.

Journal: Pulmonary therapy
Published: December 05, 2025

Clesrovimab for the Prevention of Respiratory Syncytial Virus Lower Respiratory Tract Disease in Infants.

Clesrovimab for the Prevention of Respiratory Syncytial Virus Lower Respiratory Tract Disease in Infants.

Journal: The Journal of pharmacy technology : jPT : official publication of the Association of Pharmacy Technicians
Published: December 02, 2025

Clesrovimab approval for RSV: a lifesaving opportunity for global infant health equity.

Clesrovimab approval for RSV: a lifesaving opportunity for global infant health equity.

Journal: Annals of medicine and surgery (2012)
Published: November 22, 2025

The Evolving Landscape of Respiratory Syncytial Virus (RSV) Prophylaxis in Infants.

The Evolving Landscape of Respiratory Syncytial Virus (RSV) Prophylaxis in Infants.

Journal: Cureus
Published: November 22, 2025
Showing 1-12 of 1,486

Last Updated: 04/28/2026